Abstract：
The technique of engineering drug delivery vehicles continues to develop, which bring enhancements in working more efficiently and minimizing side effects to make it more effective and safer. The intense capability of therapeutic agents to remain undamaged in a harsh extracellular environment is helpful to the success of drug development efforts. With this in mind, alterations of biopharmaceuticals with enhanced stability and decreased immunogenicity have been an increasingly active focus of such efforts. Red blood cells (RBCs), also known as erythrocytes have undergone extensive scrutiny as potential vehicles for drug delivery due to their remarkable attributes over the years of research. These include intrinsic biocompatibility, minimal immunogenicity, flexibility, and prolonged systemic circulation. Throughout the course of investigation, a diverse array of drug delivery platforms based on RBCs has emerged. These encompass genetically engineered RBCs, non-genetically modified RBCs, and RBC membrane-coated nanoparticles, each devised to cater to a range of biomedical objectives. Given their prevalence in the circulatory system, RBCs have gained significant attention for their potential to serve as biomimetic coatings for artificial nanocarriers. By virtue of their surface emulation capabilities and customizable core materials, nanocarriers mimicking these RBCs, hold considerable promise across a spectrum of applications, spanning drug delivery, imaging, phototherapy, immunomodulation, sensing, and detection. These multifaceted functionalities underscore the considerable therapeutic and diagnostic potential across various diseases. Our proposed review provides the synthesis of recent strides in the theranostic utilization of erythrocytes in the context of cancer. It also delves into the principal challenges and prospects intrinsic to this realm of research. The focal point of this review pertains to accentuating the significance of erythrocyte-based theranostic systems in combating cancer. Furthermore, it precisely records the latest and the most specific methodologies for tailoring the attributes of these biomimetic nanoscale formulations, attenuating various discoveries for the treatment and management of cancer.
摘要：
工程药物输送工具的技术不断发展，这带来了更有效的工作和最大限度地减少副作用的增强，使其更有效和更安全。治疗剂在恶劣的细胞外环境中保持不受损伤的强烈能力有助于药物开发努力的成功。考虑到这一点，具有增强的稳定性和降低的免疫原性的生物药物的改变已成为此类努力的日益活跃的焦点。红细胞（RBC），也被称为红细胞，由于它们在多年的研究中具有显著的特性，作为药物输送的潜在载体，已经经历了广泛的审查。这些包括内在的生物相容性，最小的免疫原性，灵活性,和延长的体循环。在整个调查过程中，基于红细胞的各种药物递送平台已经出现.这些包括基因工程改造的红细胞，非转基因红细胞，和红细胞膜包覆的纳米颗粒，每个设计迎合一系列生物医学目标。鉴于它们在循环系统中的流行，RBC因其作为人造纳米载体的仿生涂层的潜力而获得了极大的关注。凭借其表面仿真能力和可定制的核心材料，纳米载体模仿这些红细胞，在一系列应用中拥有相当大的前景，跨越药物输送，成像,光疗,免疫调节,传感,和检测。这些多方面的功能强调了各种疾病的相当大的治疗和诊断潜力。我们提议的综述提供了在癌症背景下对红细胞进行治疗的最新进展。它还深入研究了这一研究领域固有的主要挑战和前景。这篇综述的重点是强调基于红细胞的治疗诊断系统在抗击癌症中的重要性。此外，它精确地记录了定制这些仿生纳米级配方属性的最新和最具体的方法，削弱癌症治疗和管理的各种发现。
